BACKGROUND: Epidemiologic studies show that exposure to particulate air pollution is associated with asthma exacerbation. Ultrafine particles (diameter <100 nm) may contribute to these adverse effects. OBJECTIVE: To investigate potential adjuvant activity of inhaled elemental carbon ultrafine particles (EC-UFPs) on allergic airway inflammation. METHODS: The effects of ultrafine particle inhalation on allergic airway inflammation was analyzed in ovalbumin-sensitized mice and nonsensitized controls. Particle exposure (526 microg/m3, 24 hours) was performed 24, 96, or 168 hours before or 24 or 72 hours after ovalbumin aerosol challenge. Allergic inflammation was analyzed at different time points after allergen challenge by means of bronchoalveolar lavage cell count and cytokine/total protein assays, lung histology, and airway hyperresponsiveness. RESULTS: In sensitized mice, inhalation of ultrafine particles 24 hours before allergen challenge caused a significant increase of bronchoalveolar lavage inflammatory cell infiltrate, protein, IL-4, IL-5, and IL-13 compared with relevant controls. These adjuvant effects were dose- and time-dependent and were still present when particle exposure was performed 4 days before allergen challenge. The adjuvant effect of ultrafine particles was also documented by increased mucus production, peribronchiolar and perivascular inflammation, and enhanced airway hyperresponsiveness. In contrast, particle exposure in sensitized mice after allergen challenge caused only moderate effects, such as a delay of inflammatory infiltrate and a reduction of cytokines in bronchoalveolar lavage fluid. CONCLUSION: Exposure to ultrafine carbon particles before allergen challenge exerts strong adjuvant effects on the manifestation of allergic airway inflammation. Allergen-sensitized individuals may therefore be more susceptible to detrimental health effects of ultrafine particles.
BACKGROUND: Epidemiologic studies show that exposure to particulate air pollution is associated with asthma exacerbation. Ultrafine particles (diameter <100 nm) may contribute to these adverse effects. OBJECTIVE: To investigate potential adjuvant activity of inhaled elemental carbon ultrafine particles (EC-UFPs) on allergic airway inflammation. METHODS: The effects of ultrafine particle inhalation on allergic airway inflammation was analyzed in ovalbumin-sensitized mice and nonsensitized controls. Particle exposure (526 microg/m3, 24 hours) was performed 24, 96, or 168 hours before or 24 or 72 hours after ovalbumin aerosol challenge. Allergic inflammation was analyzed at different time points after allergen challenge by means of bronchoalveolar lavage cell count and cytokine/total protein assays, lung histology, and airway hyperresponsiveness. RESULTS: In sensitized mice, inhalation of ultrafine particles 24 hours before allergen challenge caused a significant increase of bronchoalveolar lavage inflammatory cell infiltrate, protein, IL-4, IL-5, and IL-13 compared with relevant controls. These adjuvant effects were dose- and time-dependent and were still present when particle exposure was performed 4 days before allergen challenge. The adjuvant effect of ultrafine particles was also documented by increased mucus production, peribronchiolar and perivascular inflammation, and enhanced airway hyperresponsiveness. In contrast, particle exposure in sensitized mice after allergen challenge caused only moderate effects, such as a delay of inflammatory infiltrate and a reduction of cytokines in bronchoalveolar lavage fluid. CONCLUSION: Exposure to ultrafinecarbon particles before allergen challenge exerts strong adjuvant effects on the manifestation of allergic airway inflammation. Allergen-sensitized individuals may therefore be more susceptible to detrimental health effects of ultrafine particles.
Authors: Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-07-18 Impact factor: 5.464
Authors: Jakob Löndahl; Winfried Möller; Joakim H Pagels; Wolfgang G Kreyling; Erik Swietlicki; Otmar Schmid Journal: J Aerosol Med Pulm Drug Deliv Date: 2013-10-23 Impact factor: 2.849
Authors: Barry Dellinger; Antonio D'Alessio; Andrea D'Anna; Anna Ciajolo; Brian Gullett; Heather Henry; Mel Keener; Joann Lighty; Slawomir Lomnicki; Donald Lucas; Günter Oberdörster; Demetrio Pitea; William Suk; Adel Sarofim; Kirk R Smith; Tobias Stoeger; Paige Tolbert; Ron Wyzga; Ralf Zimmermann Journal: Environ Eng Sci Date: 2008-10 Impact factor: 1.907
Authors: Jiyoun Kim; Sudha Natarajan; Louis J Vaickus; Jacqueline C Bouchard; Dominic Beal; William W Cruikshank; Daniel G Remick Journal: Am J Pathol Date: 2011-10-01 Impact factor: 4.307
Authors: Ning Li; Jack R Harkema; Ryan P Lewandowski; Meiying Wang; Lori A Bramble; Glenn R Gookin; Zhi Ning; Michael T Kleinman; Constantinos Sioutas; Andre E Nel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-06-18 Impact factor: 5.464
Authors: Eric B Brandt; Melinda Butsch Kovacic; Gerald B Lee; Aaron M Gibson; Thomas H Acciani; Timothy D Le Cras; Patrick H Ryan; Alison L Budelsky; Gurjit K Khurana Hershey Journal: J Allergy Clin Immunol Date: 2013-09-20 Impact factor: 10.793